Cyrielle G.
- Country
- France
- Department
- Gastroenterology
Research Overview
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- One-Year Real-World Effectiveness of Subcutaneous Guselkumab in Adults with Crohn’s Disease
- A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis
Data & Insights
Has run more than one trial at 337 of 509 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating complex gastrointestinal conditions, with particular emphasis on inflammatory bowel disease (IBD) management and therapeutic interventions.
- Ulcerative Colitis Treatment
- Crohn's Disease Management
- Novel Therapeutic Approaches
Their expertise extends to addressing moderate to severe manifestations of these conditions.
Postoperative Care Specialization
The investigator focuses on postoperative management and monitoring of gastrointestinal conditions, particularly in cases involving surgical interventions.
- Postoperative Recurrence Prevention
- Therapeutic Escalation Strategies
- Post-Surgery Monitoring
Their work includes evaluation of outcomes following ileocolonic anastomosis procedures.
Advanced Therapeutic Applications
The investigator has developed expertise in implementing targeted biological therapies for inflammatory bowel conditions.
- Biological Treatment Protocols
- Treatment Efficacy Assessment
- Safety Monitoring Procedures
Their focus includes evaluating innovative therapeutic approaches for gastrointestinal inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.